A28 Therapeutics is a privately-held, clinical-stage biopharmaceutical company focused on the development of its targeted oncolytic peptide platform for the treatment of multiple cancer types.
Our lead proprietary agent, AT-101, has demonstrated the potential to deliver safe and effective cancer treatment alone and in combination with multiple classes of cancer medications including immuno-oncology medications and chemotherapy. Our lead indications are metastatic ovarian cancer with liver metastases and hepatocellular carcinoma, and we are in late-stage development in both indications. In addition, A28 is preparing to study the benefits of AT-101 in combination with immuno-oncology therapeutics in various solid tumors with liver metastases.
Our goal at A28 is to deliver innovative, game-changing cancer care to patients worldwide.
Company Details
- Employees
- 6
- Founded
- -
- Address
- La Jolla, California, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://a28therapeutics.com/
- Keywords
- oncology, metastatic cancer, solid tumors, lytic peptides for cancer, oncolytic peptides, Cancer research, ovarian cancer, liver cancer, biotech.
- HQ
- La Jolla, California
A28 Therapeutics Questions
A28 Therapeutics's website is https://a28therapeutics.com/
A28 Therapeutics's LinkedIn profile is https://www.linkedin.com/company/a28-therapeutics
A28 Therapeutics has
6 employees.
View email and phone details for 6
employees at A28 Therapeutics.
A28 Therapeutics's industry is
Biotechnology Research
A28 Therapeutics's top competitors are
Polaris Genomics,
Ansun Biopharma, Inc.,
Denovicon Therapeutics,
Belharra Therapeutics,
Aptose Biosciences, Inc.,
Calcimedica,
Kyverna Therapeutics,
Peak Bio Inc.,
Akari Therapeutics, Plc,
Lengo Therapeutics.
A28 Therapeutics's categories are Biotechnology Research
A28 Therapeutics's founding year is 2021
